Paul A. Hamlin, MD

I have specialized in the care of patients with Hodgkin’s disease and non-Hodgkin lymphoma (NHL) for more than a decade as an integral member of the Lymphoma Service in the Division of Hematologic Oncology. I have served as the Director of our outpatient lymphoma clinics at MSK’s main location in Manhattan and continue to lead our innovation efforts at both MSK Basking Ridge and our 64th Street location. I also care for patients in both Manhattan and Basking Ridge.

My clinical research interests have focused on developing novel therapies and dedicated treatment programs for older patients with lymphoma, addressing the complex interplay between aging and a cancer diagnosis. As part of a multidisciplinary MSK team that cares for patients age 65 and older, I have worked to develop new treatment strategies for older patients with diffuse large B-cell, mantle cell, and Hodgkin lymphoma. Ongoing research efforts are developing new screening tools to identify patients at increased risk for treatment side effects and clinical trials specifically aimed at addressing the needs of the older patient population. We have as our shared goal the development of effective risk-adapted therapies to minimize the side effects of treatments while maximizing their effectiveness.

As a clinical researcher, I have been the principle investigator (PI) or co-PI of more than 30 clinical trials. My work continues to explore novel biologic and immunotherapeutic agents for the treatment of both NHL and Hodgkins, with phase I and II trials focused on new antibody combinations, antibody drug conjugates, immunotoxins, and small molecule inhibitors.